Reduced Final Height Outcome in Congenital Adrenal Hyperplasia under Prednisone Treatment: Deceleration of Growth Velocity during Puberty
The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Abstract
CONTEXT: Normal to decreased final height (FH) has been reported in patients with congenital adrenal hyperplasia (CAH). OBJECTIVE: The objective was to determine FH outcome and influences of steroid treatment. METHODS: The effects of glucocorticoid treatment for classical CAH were retrospectively studied in 125 patients (77 females). Growth pattern, FH, and pubertal development were recorded. RESULTS: Corrected FH was in the lower range of genetic potential [females with simple virilizing (SV)-CAH, -0.6 +/- 1.0 sd score (SDS) vs. females with salt-wasting (SW)-CAH, -0.6 +/- 0.9 SDS; males with SV-CAH, -1.1 +/- 0.9 SDS vs. males with SW-CAH, -0.9 +/- 0.9 SDS]. Total pubertal growth was significantly reduced in comparison with a reference population (females with SV-CAH, 11.9 +/- 6.5 cm, and females with SW-CAH, 13.8 +/- 7.6 cm vs. reference 20.3 +/- 6.8 cm, P < 0.01; and males with SV-CAH, 15.4 +/- 6.6 cm, and males with SW-CAH, 18.5 +/- 6.9 cm vs. reference 28.2 +/- 8.2 cm, P < 0.01). Thirty-three patients had been treated with prednisone, which resulted in reduced FH compared with patients (n = 92) treated with hydrocortisone (-1.0 +/- 0.9 SDS vs.-0.6 +/- 0.9 SDS; P < 0.05). FH correlated negatively with hydrocortisone dose given at the start of puberty (r = -0.3; P < 0.05). Pubertal development started early in boys [9.8 +/- 2.3 yr (SV) and 10.6 +/- 1.9 yr (SW)] and was timely in girls [9.8 +/- 1.9 yr (SV) and 10.3 +/- 1.5 yr (SW), menarche at 13.3 +/- 1.7 yr (SV) and 13.7 +/- 1.5 yr (SV)]. CONCLUSION: Patients with CAH are able to achieve adequate FH with conventional therapy. Total pubertal growth is significantly decreased, and treatment with prednisone results in decreased FH. In addition to biochemical analysis, treatment should be adjusted to normal growth velocity, especially during puberty.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hydrocortisone is the preferred glucocorticoid in children with CAH owing to its short half-life and the fact that it has the lowest growth suppressing effect of available glucocorticoids24,28.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [28]
In the citing paper
“However, adult height correlates negatively with glucocorticoid dose during puberty, especially doses of hydrocortisone exceeding 17 mg/m2 per day28.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [28]
In the citing paper
“The adult height of patients with CAH correlates negatively with the dose of GC administered in early puberty; patients treated with ,20 mg of HC/m 2 per day at the start of puberty are significantly taller than those given higher HC doses (187).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [187]
In the citing paper
“During childhood, the preferred GC is HC because its short half-life minimizes the adverse side effects typical of longer-acting, more potent GCs, especially growth suppression (Table 2) (187).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [187]
Citations
Cites
RADIOGRAPHIC ATLAS OF SKELETAL DEVELOPMENT OF THE HAND AND WRIST
GREULICH, W. W., & PYLE, S. I. (1959) · The American Journal Of The Medical Sciences · doi:10.1097/00000441-195909000-00030 · Cited by 5,585
Body mass index reference curves for the UK, 1990.
Cole, T. J., Freeman, J. V., & Preece, M. A. (1995) · Archives of Disease in Childhood · doi:10.1136/adc.73.1.25 · Cited by 2,047
Congenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Prader, A., Largo, R. H., Molinari, L., & Issler, C. (1989) · PubMed · Cited by 814
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
Self-citationMulaikal, R. M., Migeon, C. J., & Rock, J. A. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701223160402 · Cited by 361
Pubertal development in Swiss boys.
Rh, L., & Prader, A. (1983) · PubMed · Cited by 234
Long Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia1
Cabrera, M. S., Vogiatzi, M. G., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7668 · Cited by 204
Pubertal development in Swiss girls.
Largo, R. H., & Prader, A. (1983) · PubMed · Cited by 200
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“patients with CAH correlates negatively with the dose of GC administered in early puberty; patients treated with,20mg of HC/m(2) per day at the start of puberty are significantly taller than those given higher HC doses (187).”
BackgroundSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Adult Height in Patients with Congenital Adrenal Hyperplasia: A Systematic Review and Metaanalysis
Muthusamy, K., Elamin, M. B., Smushkin, G., Murad, M. H., Lampropulos, J. F., Elamin, K. B., Abu Elnour, N. O., Gallegos-Orozco, J. F., Fatourechi, M. M., Agrwal, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2616 · Cited by 182
Disorders of sex development (DSDs), their presentation and management in different cultures
Warne, G. L., & Raza, J. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9084-2 · Cited by 149
Bonfig, W., Dalla Pozza, S. B., Schmidt, H., Pagel, P., Knorr, D., & Schwarz, H. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0942 · Cited by 136
Self-citationManagement of adolescents with congenital adrenal hyperplasia
Merke, D. P., & Poppas, D. P. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70138-4 · Cited by 134
Approach to the Adult with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Merke, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2417 · Cited by 132
“(8). Longer-acting glucocorticoids are generally avoided in children because of potential growth suppression ( 9 ), but this requires further study.”
BackgroundAromatase inhibitors in pediatrics
Wit, J. M., Hero, M. T., & Nuñez, S. B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.161 · Cited by 125
“Congenital adrenal hyperplasia Long-term studies on growth in children with the most common form of congenital adrenal hyperplasia, steroid 21-hydroxylase deficiency, who are treated with corticosteroids and mineralocorticoids, have shown that average adult height is decreased, presumably caused by a combination of an…”
BackgroundManagement challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Management of the child with congenital adrenal hyperplasia
Hindmarsh, P. C. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.010 · Cited by 120
Health Problems in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Reisch, N., Arlt, W., & Krone, N. (2011) · Hormone Research in Paediatrics · doi:10.1159/000327794 · Cited by 106
“and reduced final height outcome under treatment with prednisone, a synthetic steroid with considerably longer half-life [”
BackgroundRiepe, F. G., & Sippell, W. G. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9053-1 · Cited by 108
“6 SDS depending on the severity of the disease [107].”
BackgroundChakhtoura, Z., Bachelot, A., Samara-Boustani, D., Ruiz, J.-C., Donadille, B., Dulon, J., Christin-Maître, S., Bouvattier, C., Raux-Demay, M.-C., Bouchard, P., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0887 · Cited by 90
“We noted low final height compared to target height, consistent with former publications (25-28), while onset-pubertal height was normal.”
ResultShulman, D. I., Francis, G. L., Palmert, M. R., & Eugster, E. A. (2008) · PEDIATRICS · doi:10.1542/peds.2007-2081 · Cited by 93
Whittle, E., & Falhammar, H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00136 · Cited by 87
“[15] found that prednisolone treatmentwas associated with higher hydrocortisone-equivalent doses and significantly reduced final height when compared with hydrocortisone.”
BackgroundThe Use of Bone Age in Clinical Practice – Part 2
Martin, D. D., Wit, J. M., Hochberg, Z., van Rijn, R. R., Fricke, O., Werther, G. A., Cameron, N., Hertel, T., Wudy, S. A., Butler, G. E., et al. (2011) · Hormone Research in Paediatrics · doi:10.1159/000329374 · Cited by 97
Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): An update
Trapp, C. M., & Oberfield, S. E. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.009 · Cited by 81
“Adult height approaching expected target height has been reported in patients who adhere to strict monitoring [39–41].”
BackgroundGlucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia
Han, T. S., Stimson, R. H., Rees, D. A., Krone, N., Willis, D. S., Conway, G. S., Arlt, W., Walker, B. R., Ross, R. J., & (CaHASE), U. K. C. A. H. A. S. E. (2013) · Clinical Endocrinology · doi:10.1111/cen.12045 · Cited by 70
Rangaswamaiah, S., Gangathimmaiah, V., Nordenstrom, A., & Falhammar, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00493 · Cited by 59
Webb, E. A., & Krone, N. P. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.04.002 · Cited by 72
“Exposure to high concentrations of glucocorticoids suppresses growth, increases blood pressure and can cause osteoporosis and iatrogenic Cushing’s syndrome (34,83,84,91,98).”
BackgroundLivadas, S., & Bothou, C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00366 · Cited by 57
Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency
Oprea, A., Bonnet, N., Pollé, O. G., & Lysy, P. A. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818821294 · Cited by 69
Congenital adrenal hyperplasia – pharmacologic interventions from the prenatal phase to adulthood
Claahsen-van der Grinten, H. L., Stikkelbroeck, N. M. M. L., Otten, B. J., & Hermus, A. R. M. M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.05.004 · Cited by 53
Congenital adrenal hyperplasia: an update in children
Trapp, C. M., Speiser, P. W., & Oberfield, S. E. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328346938c · Cited by 50
Endocrine Dysfunction in X-Linked Adrenoleukodystrophy
Burtman, E., & Regelmann, M. O. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.01.003 · Cited by 54
Miller, B. S., Spencer, S. P., Geffner, M. E., Gourgari, E., Lahoti, A., Kamboj, M. K., Stanley, T. L., Uli, N. K., Wicklow, B. A., & Sarafoglou, K. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2019-000999 · Cited by 49
Growth and development in children with classic congenital adrenal hyperplasia
Bonfig, W. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000308 · Cited by 52
“6 years in boys with salt-wasting CAH [11].”
BackgroundSelf-citationGlucocorticoid replacement regimens for treating congenital adrenal hyperplasia
Ng, S. M., Stępień, K. M., & Krishan, A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012517.pub2 · Cited by 58
“Nine trials were not RCTs or quasi-RCTs (Ajish 2014; Bonfig 2007; Charmandari 2001; Mallappa 2015; Merza 2006; Neumann 2018; Panamonta 2003; PRENATAL DEX; Verma 2010) and the remaining trials did not have HC regimens as the intervention.”
BackgroundMethodInfluentialSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/494173 · Cited by 45
“The GC of first choice for maintenance therapy of children with CAH is hydrocortisone [13] in tablet form.”
BackgroundNermoen, I., Brønstad, I., Fougner, K. J., Svartberg, J., Øksnes, M., Husebye, E. S., & Løvås, K. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0196 · Cited by 43
Management of Childhood Congenital Adrenal Hyperplasia-An Integrative Review of the Literature
Fleming, L., Riper, M. V., & Knafl, K. (2017) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2017.02.004 · Cited by 19
Challenges in treatment of patients with non-classic congenital adrenal hyperplasia
Adriaansen, B. P. H., Schröder, M. A. M., Span, P. N., Sweep, F. C. G. J., van Herwaarden, A. E., & der Grinten, H. L. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064024 · Cited by 51
Bacila, I., Freeman, N., Daniel, E., Sandrk, M., Bryce, J., Ali, S. R., Yavas Abali, Z., Atapattu, N., Bachega, T. A., Balsamo, A., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1249 · Cited by 36
Self-citationSchaeffer, T. L., Tryggestad, J. B., Mallappa, A., Hanna, A., Krishnan, S., Chernausek, S. D., Chalmers, L. J., Reiner, W. G., Kropp, B. P., & Wisniewski, A. B. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/692439 · Cited by 45
“Although encouraging, data on such treatment approaches are limited and thus these therapies are not part of our routine management of patients—most of whom reach an adult height within the normal range despite having received solely conventional hormone replacement [24].”
BackgroundCurrent and Novel Treatment Strategies in Children with Congenital Adrenal Hyperplasia
Nordenström, A., Falhammar, H., & Lajić, S. (2022) · Hormone Research in Paediatrics · doi:10.1159/000522260 · Cited by 41
“A study by Bonfig et al. [94] on 125 children with CAH treated with prednisone until final height was reached showed a reduced final height (-1SDS) compared to a target height.”
BackgroundMethodMooij, C. F., Webb, E. A., Claahsen van der Grinten, H. L., & Krone, N. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2016-311910 · Cited by 31
Growth curves for congenital adrenal hyperplasia from a national retrospective cohort
Bretones, P., Riche, B., Pichot, E., David, M., Roy, P., Tardy, V., Kassaï, B., Gaillard, S., Bernoux, D., Morel, Y., et al. (2016) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2016-0156 · Cited by 31
Pijnenburg-Kleizen, K. J., Thomas, C. M. G., Otten, B. J., Roeleveld, N., & der Grinten, H. L. C. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0006 · Cited by 35
Novel treatments for congenital adrenal hyperplasia
Schröder, M. A. M., & der Grinten, H. L. C. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09717-w · Cited by 35
“The use of long acting more potent glucocorticoids should be avoided as these preparations can lead to growth suppression and features of hypercortisolism [26].”
BackgroundNoppe, G., van Rossum, E. F. C., Vliegenthart, J., Koper, J. W., & van den Akker, E. L. T. (2014) · Clinical Endocrinology · doi:10.1111/cen.12551 · Cited by 29
Congenital Adrenal Hyperplasia: A Lifelong Disorder
Hughes, I. (2007) · Hormone Research in Paediatrics · doi:10.1159/000110585 · Cited by 27
“It is crucial to respond rapidly with appropriate diagnostic investigation and potential life-saving treatment by the neonatologist, paediatric endocrinologist, paediatric urologist and geneticist. Increasingly, the clinical psychologist is engaged at this early stage when key issues such as gender assignment are para…”
BackgroundClinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)
Ishii, T., Kashimada, K., Amano, N., Takasawa, K., Nakamura‐Utsunomiya, A., Yatsuga, S., Mukai, T., Ida, S., Isobe, M., Fukushi, M., et al. (2022) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2022-0009 · Cited by 37
“Height has been reported to increase at doses < 20 mg/m2/d at the onset of puberty (100).”
BackgroundGrowth and Reproductive Outcomes in Congenital Adrenal Hyperplasia
Nebesio, T. D., & Eugster, E. A. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/298937 · Cited by 34
“Overtreatment of CAH at the onset of puberty may result in a less profound growth spurt due to an attenuated influence of sex steroids on growth [32].”
BackgroundInfluentialValidation of automatic bone age determination in children with congenital adrenal hyperplasia
Martin, D. D., Heil, K. F., Heckmann, C., Zierl, A., Schaefer, J. F., Ranke, M. B., & Binder, G. (2013) · Pediatric Radiology · doi:10.1007/s00247-013-2744-8 · Cited by 29
“Finding the correct dosage poses a challenge because even slight overdoses of glucocorticoids will curb growth over time [6, 8–11].”
BackgroundCongenital adrenal hyperplasia
Hughes, I. A. (2005) · Oxford University Press eBooks · doi:10.1016/j.mpmed.2009.05.007 · Cited by 28
Growth in Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Dörr, H. G. (2007) · Hormone Research in Paediatrics · doi:10.1159/000110587 · Cited by 31
“The final height SDS – target height SDS for the patients at the authors’ institution was –1.03. The meta-analysis of 561 patients revealed a mean final height SDS of –1.37, and a mean final height SDS of –1.21 corrected for target height (204 patients). Thus, most patients with CAH lose final height.Slightly better r…”
BackgroundInfluentialTreatment of the Enlarged Clitoris
Kaefer, M. A., & Rink, R. C. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00125 · Cited by 30
“Longer-acting glucocorticoids have typically been avoided in children due to their potential for growth suppression (24).”
BackgroundRivkees, S. A. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/569680 · Cited by 31
“And when prednisone and hydrocortisone are used at 5- and 30-fold potencies relative to hydrocortisone, respectively, children will be overtreated [3, 4].”
BackgroundKocova, M., Anastasovska, V., & Falhammar, H. (2020) · Endocrine · doi:10.1007/s12020-020-02323-3 · Cited by 24
Long‐term health consequences of congenital adrenal hyperplasia
Pofi, R., Ji, X., Krone, N. P., & Tomlinson, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14967 · Cited by 30
“14 The recommended body surface area ‐ HC dose for infants and children is 10 – 15mg/m 2 per day, often administered three/four doses per day.”
Congenital Adrenal Hyperplasia: Issues in Diagnosis and Treatment in Children
Sharma, R., & Seth, A. (2013) · The Indian Journal of Pediatrics · doi:10.1007/s12098-013-1280-8 · Cited by 31
“On the other hand, the use of long-acting glucocorticoids during childhood adversely affects height [35, 36].”
BackgroundSubstitution therapy in adult patients with congenital adrenal hyperplasia
Reisch, N. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.11.002 · Cited by 24
Bachelot, A., Chakhtoura, Z., Samara-Boustani, D., Dulon, J., Touraine, P., & Polak, M. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/326275 · Cited by 21
Juan, L., Ma, H., Su, Z., Li, Y., Hongshan, C., Qiuli, C., Jun, Z., Guo, S., & Du, M. (2016) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2015-0406 · Cited by 22
Sarafoglou, K., Gonzalez‐Bolanos, M. T., Zimmerman, C. L., Boonstra, T., Yaw Addo, O., & Brundage, R. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.424 · Cited by 20
“Hydrocortisone is the drug of choice in growing children and is associated with better linear growth outcomes than long-acting glucocorticoids.(1,2) Due to its short half-life, hydrocortisone is usually given 3 times a day with a recommended daily range of 10–15mg/m(2)/day.”
BackgroundBacila, I. A., Lawrence, N., Mahdi, S., Alvi, S., Cheetham, T. D., Crowne, E. C., Das, U., Dattani, M., Davies, J. H., Gevers, E. F., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1109 · Cited by 24
Alwashih, M. A., Watson, D. G., Andrew, R., Stimson, R. H., Alossaimi, M. A., Blackburn, G. J., & Walker, B. R. (2017) · Scientific Reports · doi:10.1038/s41598-017-17220-5 · Cited by 20
Hoyer‐Kuhn, H., Huebner, A., Richter-Unruh, A., Bettendorf, M., Rohrer, T. R., Kapelari, K., Riedl, S., Mohnike, K. L., Dörr, H., Roehl, F.-W., et al. (2021) · Endocrine Connections · doi:10.1530/ec-21-0023 · Cited by 24
“14 trials available showing an association between high dose glucocorticoid treatment and short stature in adulthood (15, 18-20).”
BackgroundCordeiro, G. V., Silva, I. N., Goulart, E. M. A., das Chagas, A. J., & Kater, C. E. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000200005 · Cited by 21
“Recent data point out to the harm ful impact of glucocorticoid treatment in FH outcomes (11), and other reports suggest better outcomes after the use of lower HC doses (12-13).”
BackgroundResultDuration of Suppression of Adrenal Steroids after Glucocorticoid Administration
Fuqua, J. S., Rotenstein, D., & Lee, P. A. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/712549 · Cited by 22
“This is because of the higher potential for growth suppression with longer acting, more potent steroids [28, 29].”
Backgroundder Grinten, H. L. C., Adriaansen, B. P. H., & Falhammar, H. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae718 · Cited by 19
Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care
Balagamage, C., Arshad, A., Elhassan, Y., Said, W. B., Krone, R. E., Gleeson, H. K., & Idkowiak, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14992 · Cited by 19
“32,34 35 – 38 Hyperandrogenaemia per se is known to contribute to increased cardiovascular risk, including increased free fatty acid synthesis, reduced intrahepatic and peripheral insulin sensitivity, low ‐ grade inflammation with oxidative stress and reduced ventricular vascular coupling.”
InfluentialLow-Dose Dexamethasone Therapy from Infancy of Virilizing Congenital Adrenal Hyperplasia
Rivkees, S. A., & Stephenson, K. (2009) · International Journal of Pediatric Endocrinology · doi:10.1155/2009/274682 · Cited by 24
“When applied in the treatment of CAH, the relative potency of prednisone to hydrocortisone of 4 to 5 to 1 has been used by some groups [6].”
MethodGomes, L. G., Madureira, G., Mendonca, B. B., & Bachega, T. A. S. S. (2013) · Clinics · doi:10.6061/clinics/2013(02)oa05 · Cited by 16
Bizzarri, C., Improda, N., Maggioli, C., Capalbo, D., Roma, S., Porzio, O., Salerno, M., & Cappa, M. (2017) · Endocrine Practice · doi:10.4158/ep171751.or · Cited by 17
Troger, T., Sommer, G., Lang‐Muritano, M., Konrad, D., Kuhlmann, B., Zumsteg, U., & Flück, C. E. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab701 · Cited by 16
“4 mg/m(2)/d during adrenarche and puberty, respectively, as recommended by Bonfig et al (4, 28).”
BackgroundMethodNeumann, U., van der Linde, A., Krone, R. E., Krone, N. P., Güven, A., Güran, T., Elsedfy, H. H., Poyrazoglu, S., Darendeliler, F., Bachega, T. A. S. S., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1085 · Cited by 18
Self-citationMoreira, R. P. P., Jorge, A. A. L., Gomes, L. G., Kaupert, L. C., Filho, J. M., Mendonca, B. B., & Bachega, T. A. S. S. (2011) · Clinics · doi:10.1590/s1807-59322011000800009 · Cited by 17
Engberg, H., Nordenström, A., & Hirschberg, A. (2025) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/clinem/dgae696 · Cited by 8
Goedegebuure, W. J., & Hokken-Koelega, A. (2019) · Hormone Research in Paediatrics · doi:10.1159/000501746 · Cited by 14
Newfield, R. S. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.10.034 · Cited by 12
“Failing to adequately suppress excess androgens results in height acceleration and advanced skeletal maturation (as determined by the child’s bone age), but eventually leads to compromised final adult height [3,5,6].”
BackgroundCongenital Adrenal Hyperplasia and Related Disorders
White, P. C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00570-4 · Cited by 11
Medical treatment of classic and nonclassic congenital adrenal hyperplasia
Speiser, P. W. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8002-1_9 · Cited by 10
Congenital Adrenal Hyperplasia: Unresolved Issues
Yau, M., Khattab, A., Poppas, D. P., Ghizzoni, L., & New, M. I. (2016) · Frontiers of hormone research · doi:10.1159/000443919 · Cited by 12
Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry
Lawrence, N., Bacila, I. A., Dawson, J., Bryce, J., Ali, S., van den Akker, E. L. T., Bachega, T. A. S. S., Baronio, F., Birkebæk, N., Bonfig, W., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14796 · Cited by 11
“However, others suggest doses over 17mg/m(2)/day should only be used with care during puberty as adult height has been shown to correlate negatively with glucocorticoid dose.(1,2,8) Maintaining 17‐OH progesterone (17OHP) concentrations in the upper end of the normal range is suggested,(6) with alternative targets incl…”
BackgroundSelf-citationLong-term Growth in Congenital Adrenal Hyperplasia
Maheshwari, A., Khadilkar, V. V., Gangodkar, P. V., & Khadilkar, A. V. (2018) · The Indian Journal of Pediatrics · doi:10.1007/s12098-018-2753-6 · Cited by 11
Shaikh, A. M. A., Alghanmi., Y., Awidah, S., Bahha, A., Ahmed, M., & Soliman, A. T. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_99_19 · Cited by 12
Kawano, A., Kohno, H., & Miyako, K. (2014) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.23.27 · Cited by 9
“Decreased pubertal peak growth velocity has been reported (8, 9, 16, 17).”
BackgroundTreatment Outcomes in Congenital Adrenal Hyperplasia
Cheng, T. Q., & Speiser, P. (2012) · Advances in Pediatrics · doi:10.1016/j.yapd.2012.04.009 · Cited by 9
“When chronic hydrocortisone dosages exceed 20 mg/m/d in infants and 15 to 17 mg/m/d in adolescents [27], there is a loss of height standard deviation (SD) score and shorter adult height potential.”
Backgroundder Grinten, H. L. C., Stikkelbroeck, M., Bulten, J., & den Heyer, M. (2013) · Hormone Research in Paediatrics · doi:10.1159/000354659 · Cited by 8
Bechtold, S., Beyerlein, A., Bonfig, W., Dalla Pozza, R., Putzker, S., Otto, R., Schmidt, H., & Schwarz, H. P. (2014) · Hormone Research in Paediatrics · doi:10.1159/000362759 · Cited by 7
Self-citationKendırcı, H. N. P., Ünal, E., Dündar, İ., Buluş, A. D., Güneş, S. O., & Şıklar, Z. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-6-26-s · Cited by 11
Bancos, I., Kim, H., Cheng, H. K.-H., Rodríguez-Lee, M., Coope, H., Cicero, S., Goldsmith, H., Lin, V. H., & Jeha, G. S. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2450423 · Cited by 9
Impact of Newborn Screening on Adult Height in Patients With Congenital Adrenal Hyperplasia (CAH)
Hoyer‐Kuhn, H., Eckert, A. J., Binder, G., Bonfig, W., Dübbers, A., Riedl, S., Woelfle, J., Dörr, H. G., & Holl, R. W. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad307 · Cited by 9
Self-citationRestoration of Height after 11 Years of Letrozole Treatment in 11β-Hydroxylase Deficiency
Atay, Z., Turan, S., Buğdaycı, O., Güran, T., & Bereket, A. (2019) · Hormone Research in Paediatrics · doi:10.1159/000501456 · Cited by 8
Endocrine, cardiac and neuropsychological aspects of adult congenital adrenal hyperplasia
Ridder, L. O. R., Balle, C. M., Skakkebaek, A. H., Lind‐Holst, M., Nielsen, M. M., Hermann, A. P., Hansen, S., Nielsen, D. G., Knorr, S., Andersen, N. H., et al. (2024) · Clinical Endocrinology · doi:10.1111/cen.15055 · Cited by 6
“28 The decreased height in individuals with CAH may be due to excessive glucocorticoid treatment during childhood which stunts growth in childhood and adolescence and may increase BMI.”
BackgroundNg, S. M., & Stępień, K. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012517 · Cited by 6
Ahmed, S. E. A. M., Soliman, A. T., Ramadan, M. A. E. F., Elawwa, A., Abugabal, A. M. S., Emam, M. H. A., & Sanctis, V. D. (2019) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v90i3.8732 · Cited by 14
“Up till now, debate still exists about the difference in the effect on growth and metabolism when different GC formulations are used for treatment of CAH (9-15).”
BackgroundClinical Characteristics of 46,XX Males with Congenital Adrenal Hyperplasia
Erdeve, Ş. S., Aycan, Z., Çetinkaya, S. Ç., Öztürk, A. P., Baş, F., Poyrazoğlu, Ş., Darendelıler, F., Özsu, E., Şıklar, Z., Demiral, M., et al. (2020) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2020.2020.0216 · Cited by 8
“This may be due to the well-known negative effect of excessive glucocorticoid doses on growth (21,22).”
BackgroundVieira, A., Paiva, S., Baptista, C. F., Ruas, L., Silva, J., Gonçalves, J., Carrilho, F., & Carvalheiro, M. C. (2011) · Acta Médica Portuguesa · doi:10.20344/amp.338 · Cited by 6
Völkl, T. M. K., Rauh, M., Schöfl, C., & Dörr, H. G. (2011) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2011.05.001 · Cited by 5
“1 SDS for males with SV CAH, respectively [12].”
BackgroundDebor, B., Pozza, S. B., Reisch, N., Schmidt, H., & Dubinski, I. (2023) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2023-0169 · Cited by 5
Self-citationCui, X., & Li, P. (2024) · Reproductive Health · doi:10.1186/s12978-024-01874-2 · Cited by 4
“However, prenatal use of DEX may be associated with fetal developmental defects [3, 39, 40] 、 low birth weight [41] 、 decreased fetal length [42] 、 cognitive impairment [43], and may even permanently affect the expression of carbohydrate homeostasis-related genes that alter the normal effects of…”
Gonçalves, E. M., de Lemos‐Marini, S. H. V., de Mello, M. P., Baldin, A. D., de Carvalho, W. R. G., Farias, E. S., & Guerra‐Júnior, G. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000300005 · Cited by 8
“O tratamento de reposição com glicocorticoide, apesar dos avanços, ainda é de difícil controle e pode levar tanto à situação de tratamento em subdose, com sinais de hiperandrogenismo, como virilização em ambos os gêneros, aumento da massa magra, aceleração da maturação esquelética, fusão prematura das cartilagens de c…”
BackgroundSella, A. C., & Halper, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-52215-5_49 · Cited by 4
Doğruel, D., Turan, İ., Gürbüz, F., Celiloğlu, C., & Yüksel, B. (2022) · HORMONES · doi:10.1007/s42000-022-00354-1 · Cited by 5
“[15] determined that high androgen levels in the prepubertal period cause short FH.”
BackgroundResultInfluentialRivkees, S. A. (2008) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2008.21.4.297 · Cited by 4
Abalı, Z. Y., Yıldız, M., Abalı, S., Moniri, A., Baş, F., Önal, H., Çilsaat, G., Toksoy, G., Turan, S., Poyrazoğlu, Ş., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf612 · Cited by 5
Metadata
- Authors
- Bonfig, W., Bechtold, S., Schmidt, H., Knorr, D., & Schwarz, H. P.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Bonfig, Walter
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-05-01
- Volume
- 92
- Issue
- 5
- Pages
- 1635-1639
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2160090915
- Cited by
- 167
- References
- 40
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 7 · 2023: 6 · 2022: 10 · 2021: 7 · 2020: 6 · 2019: 15 · 2018: 4 · 2017: 7 · 2016: 9 · 2015: 1 · 2014: 8 · 2013: 11 · 2012: 6
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, adult height, prednisone, cortisol, glucocorticoid therapy, growth rate, puberty, pubertal growth, simple virilizing CAH, salt-wasting CAH, menarche, growth hormone therapy, genetic potential, dose-response relationship, short stature, children and adolescents, sex differences, puberty timing
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Body Height, Breast, Child, Female, Growth, Hormones, Humans, Hydrocortisone, Male, Prednisone, Puberty, Retrospective Studies, Steroid 21-Hydroxylase, Testis, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.